Breaking News

U.K. August Services PMI Rises to 60.5, Beating Median Forecast of 58.5
Tweet TWEET

Rosetta Genomics Added to Ocean Tomo 300 Patent Index

            Rosetta Genomics Added to Ocean Tomo 300 Patent Index

Ranked Among the Top Companies Valued on Intellectual Property

PR Newswire

PHILADELPHIA and REHOVOT, Israel, Nov. 15, 2012

PHILADELPHIA and REHOVOT, Israel, Nov.15, 2012 /PRNewswire/ --Rosetta
Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of
microRNA-based molecular diagnostics, today announced the Company's addition
to the Ocean Tomo 300^® Patent Index ("OT300" or "the Index"), a diversified
listing of the 300 companies whose equities trade on major U.S. exchanges that
own the most valuable patent portfolios relative to the book value of the
company and the only index based on the value of corporate intellectual
property. The Index is priced and published by the NYSE Euronext and since
its inception in 2007, has outperformed the S&P^® 500 by 635 basis points.

Rosetta Genomics maintains a robust intellectual property strategy to protect
its leadership position in microRNA technology. Rosetta's portfolio includes
29 issued patents, including 25 in the U.S. In addition, Rosetta has 49
patent applications, including 21 in the U.S.

"Rosetta Genomics pioneered the development ofmicroRNA technology. We
believe we have the earliest and broadest patents and patent applications
related to composition of matter on microRNAs, which is a key differentiating
factor of our technology," noted Kenneth A. Berlin, President and Chief
Executive Officer of Rosetta Genomics. "We are pleased to have Rosetta
included in the Ocean Tomo 300® Patent Indexas it provides a meaningful
benchmark for the performance of companies in today's intangible asset-driven
economy. Of note, the Index includes only 60 healthcare companies and only
two other lab testing businesses."

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by
Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type
in primary and metastatic cancer including CUP. miRview^® meso diagnoses
mesothelioma, a cancer connected to asbestos exposure. miRview^® lung
accurately identifies the four main subtypes of lung cancer using small
amounts of tumor cells. miRview^® kidney accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC,
chromophobe RCC and oncocytoma. miRview^® tests are designed to provide
objective diagnostic data; it is the treating physician's responsibility to
diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta
Genomics estimates that 200,000 patients a year may benefit from the miRview^®
mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and
226,000 patients from miRview^® lung. The Company's assays are offered
directly by Rosetta Genomics in the U.S., and through distributors around the
world. For more information, please visit www.mirviewdx.com. Parties
interested in ordering the test can contact Rosetta Genomics at (215) 382-9000
ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular
diagnostics. Founded in 2000 Rosetta's integrative research platform
combining bioinformatics and state-of-the-art laboratory processes has led to
the discovery of hundreds of biologically validated novel human microRNAs.
Building on its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the development
and commercialization of a full range of microRNA-based diagnostic tools.
Rosetta's miRview^® product line is commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. Frost & Sullivan
recognized Rosetta Genomics with the 2012 North American Next Generation
Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations,
plans and prospects, including without limitation, statements relating to
Rosetta's capitalization of its microRNA platform and Rosetta's patent
portfolio constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of Rosetta's
Annual Report on Form 20-F for the year ended December 31, 2011 as filed with
the SEC. In addition, any forward-looking statements represent Rosetta's
views only as of the date of this release and should not be relied upon as
representing its views as of any subsequent date. Rosetta does not assume any
obligation to update any forward-looking statements unless required by law.

Company Contact: Investor Contacts:
Rosetta Genomics LHA
Ken Berlin, President & CEO  Anne Marie Fields
(215) 382-9000, ext. 326  (212) 838-3777
investors@rosettagenomics.com    afields@lhai.com
                                                     or
                                                     Bruce Voss
                                                     (310) 691-7100
                                                     bvoss@lhai.com

SOURCE Rosetta Genomics Ltd.
 
Press spacebar to pause and continue. Press esc to stop.